BIOYF (BIOYF) Stock Price & Analysis
BIOYF (BIOYF) fell 0.19% to USD 10.4 as of July 25, 2026 at 17:09 UTC, according to Nexqual real-time market data.
BIOYF last closed at USD 10.42; the session ranged USD 10.4–10.46 on volume of 500 shares. Market capitalization is $117.85M, with a 52-week range of USD 7.63–12 (PNK). Source: Nexqual, July 25, 2026 at 17:09 UTC.
Key Statistics (as of July 25, 2026 at 17:09 UTC)
| Price | USD 10.4 |
|---|---|
| Change | ▼ 0.19% (down) |
| Previous Close | USD 10.42 |
| Open | USD 10.4 |
| Day Range | USD 10.4 – 10.46 |
| 52-Week Range | USD 7.63 – 12 |
| Volume | 500 shares |
| Market Cap | $117.85M |
| Exchange | PNK |
Technical Analysis (BIOYF)
Nexqual's technical model rates BIOYF "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 17:09 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.18 (neutral) |
| vs SMA50 | Above (USD 10.17) |
| MACD | 0.08 (positive) |
Analyst Ratings (BIOYF)
Wall Street analysts rate BIOYF "None", per Nexqual as of July 25, 2026 at 17:09 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOYF)
| Next Earnings Date | 2026-08-27 |
|---|---|
| Revenue Estimate | $17.60M |
Source: Nexqual, July 25, 2026 at 17:09 UTC.
Financials & Fundamentals (BIOYF)
| Total Revenue | $45.98M |
|---|---|
| Revenue Growth (YoY) | +26.70% |
| Gross Margin | +75.67% |
| Operating Margin | +24.61% |
| Profit Margin | +19.65% |
| ROE | +22.31% |
| Debt / Equity | 11.66 |
| Current Ratio | 1.89 |
| Total Cash | $10.90M |
| Total Debt | $5.25M |
| Free Cash Flow | $6.05M |
Source: Nexqual, July 25, 2026 at 17:09 UTC.
Financial Health Score (BIOYF)
Nexqual rates BIOYF's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 17:09 UTC.
| Growth | Strong — Revenue +23% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $11M cash vs $5M debt, net cash position |
| Cash Flow | Solid — FCF $6M, 14% margin |
| Efficiency | Strong — ROE 22%, ROA 13.8% |
Ownership (BIOYF)
| Insider Ownership | +34.86% |
|---|---|
| Institutional Ownership | +4.00% |
| Shares Outstanding | 11.33M |
| Float | 9.25M |
Source: Nexqual, July 25, 2026 at 17:09 UTC.
Leadership (BIOYF)
BIOYF is led by René C. Goehrum (age 66), Chairman, CEO & President, per Nexqual as of July 25, 2026 at 17:09 UTC.
| Chairman, CEO & President | René C. Goehrum (age 66) |
|---|---|
| VP of Finance & CFO | Robert J. March |
| Vice President of Corporate Development | Joost van der Mark |
| Director of Human Resources | Neelu Atwal |
Major Backers & Investors (BIOYF)
Notable institutional backers of BIOYF include Grandeur Peak Global Trust-Grandeur Peak Global Contrarian Fund, according to Nexqual as of July 25, 2026 at 17:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Grandeur Peak Global Trust-Grandeur Peak Global Contrarian Fund | 2.25% |
Source: Nexqual, July 25, 2026 at 17:09 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CPHRF | Cipher Pharmaceuticals, Inc. | USD 11.71 | ▲ 0.26% |
| SMTI | Sanara MedTech Inc. | USD 25.56 | ▲ 0.08% |
| PFHO | Pacific Health Care Organizatio | USD 0.83 | ▲ 0% |
| WFCF | Where Food Comes From, Inc. | USD 12.49 | ▲ 3.14% |
| LEAT | Leatt Corp. | USD 12.91 | ▲ 0.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 17:09 UTC. This page is informational and not investment advice.